Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma

© 2018, © 2018 The Author(s). Published by Taylor & Francis. Response to targeted therapies is limited by the activation or inhibition of feedback loops. Here we report the ubiquitin specific peptidase 28/F-box WD repeat-containing protein 7 (USP28/FBW7) complex functions as a negative regulat...

Full description

Bibliographic Details
Main Authors: Saei, A., Eichhorn, Pieter
Format: Journal Article
Published: 2018
Online Access:http://hdl.handle.net/20.500.11937/72815
_version_ 1848762849347764224
author Saei, A.
Eichhorn, Pieter
author_facet Saei, A.
Eichhorn, Pieter
author_sort Saei, A.
building Curtin Institutional Repository
collection Online Access
description © 2018, © 2018 The Author(s). Published by Taylor & Francis. Response to targeted therapies is limited by the activation or inhibition of feedback loops. Here we report the ubiquitin specific peptidase 28/F-box WD repeat-containing protein 7 (USP28/FBW7) complex functions as a negative regulator of mitogen-activated protein kinase (MAPK) pathway by targeting v-raf murine sarcoma viral oncogene homolog B (BRAF) for degradation, a process which is lost in a large proportion of BRAF mutant melanoma patients, resulting in resistance to BRAF inhibitor therapies.
first_indexed 2025-11-14T10:54:06Z
format Journal Article
id curtin-20.500.11937-72815
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T10:54:06Z
publishDate 2018
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-728152018-12-13T09:33:39Z Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma Saei, A. Eichhorn, Pieter © 2018, © 2018 The Author(s). Published by Taylor & Francis. Response to targeted therapies is limited by the activation or inhibition of feedback loops. Here we report the ubiquitin specific peptidase 28/F-box WD repeat-containing protein 7 (USP28/FBW7) complex functions as a negative regulator of mitogen-activated protein kinase (MAPK) pathway by targeting v-raf murine sarcoma viral oncogene homolog B (BRAF) for degradation, a process which is lost in a large proportion of BRAF mutant melanoma patients, resulting in resistance to BRAF inhibitor therapies. 2018 Journal Article http://hdl.handle.net/20.500.11937/72815 10.1080/23723556.2018.1497862 restricted
spellingShingle Saei, A.
Eichhorn, Pieter
Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
title Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
title_full Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
title_fullStr Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
title_full_unstemmed Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
title_short Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
title_sort ubiquitination and adaptive responses to braf inhibitors in melanoma
url http://hdl.handle.net/20.500.11937/72815